Argenica (ASX:AGN) stroke drug judged safe for continued efficacy testing
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.
A first dosing marks the official beginning of Phase 2 clinical trials to prove ARG-007’s efficacy in treating victims of acute ischaemic stroke.
A Pediatric Disease Designation for Argenica’s therapeutic opens the post-clinical way for a priority review and path to market.
More positive Travelan results support progression toward Phase 3 clinical trials and a pivotal FDA registration.
Emyria authorised to prescribe MDMA to treat Australian’s with PTSD.
An Orphan Designation opens up tax credits for clinical trials, user fee exemptions, and potentially seven years of market exclusivity.